Form 4 for PRME Prime Medicine, Inc.
Accepted 2022-10-26 00:00:00 ET · period of report 2022-10-24 · accession 0001628280-22-027122 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2022-10-26 | 2022-10-24 | PRME | Cahill Thomas | Dir | C - Cnv Deriv | — | +4.91M | 4.91M | New | — |
| DI | 2022-10-26 | 2022-10-24 | PRME | Cahill Thomas | Dir | P - Purchase | $17.00 | +400.0K | 5.31M | +8% | +$6.80M |
| DMI | 2022-10-26 | 2022-10-24 | PRME | Cahill Thomas | Dir | C - Cnv Deriv | $0.00 | -15.25M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-10-24 | C | A | 4,905,679 | — | 4,905,679 | I By Newpath Partners, L.P. | — | — | (F1) The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date. (F2) Represents shares held directly by Newpath Partners, L.P. ("Newpath LP"). Newpath Partners GP, L.P. ("Newpath GP LP") is the general partner of Newpath LP. Newpath Partners GP, LLC ("Newpath GP LLC") is the general partner of Newpath GP LP. The Reporting Person is a managing member of Newpath GP LLC, and disclaims beneficial ownership of the shares held directly by Newpath LP except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. |
| 2 | Common | Common Stock | 2022-10-24 | P | A | 400,000 | $17.00 | 5,305,679 | I By Newpath Partners, L.P. | — | — | (F3) Reflects shares purchased by Newpath LP in the Issuer's initial public offering. (F2) Represents shares held directly by Newpath Partners, L.P. ("Newpath LP"). Newpath Partners GP, L.P. ("Newpath GP LP") is the general partner of Newpath LP. Newpath Partners GP, LLC ("Newpath GP LLC") is the general partner of Newpath GP LP. The Reporting Person is a managing member of Newpath GP LLC, and disclaims beneficial ownership of the shares held directly by Newpath LP except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. |
| 3 | Derivative | Series B Convertible Preferred Stock | 2022-10-24 | C | D | 5,250,781 | $0.00 | 0 | I By Newpath Partners, L.P. | — · — to — | 1,689,005 Common Stock | (F2) Represents shares held directly by Newpath Partners, L.P. ("Newpath LP"). Newpath Partners GP, L.P. ("Newpath GP LP") is the general partner of Newpath LP. Newpath Partners GP, LLC ("Newpath GP LLC") is the general partner of Newpath GP LP. The Reporting Person is a managing member of Newpath GP LLC, and disclaims beneficial ownership of the shares held directly by Newpath LP except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. (F1) The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date. |
| 4 | Derivative | Series A Convertible Preferred Stock | 2022-10-24 | C | D | 9,999,999 | $0.00 | 0 | I By Newpath Partners, L.P. | — · — to — | 3,216,674 Common Stock | (F2) Represents shares held directly by Newpath Partners, L.P. ("Newpath LP"). Newpath Partners GP, L.P. ("Newpath GP LP") is the general partner of Newpath LP. Newpath Partners GP, LLC ("Newpath GP LLC") is the general partner of Newpath GP LP. The Reporting Person is a managing member of Newpath GP LLC, and disclaims beneficial ownership of the shares held directly by Newpath LP except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. (F1) The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date. |